Northwest & Ethical Investments L.P. Sells 1,357 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Northwest & Ethical Investments L.P. lowered its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 4.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 27,513 shares of the medical research company’s stock after selling 1,357 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Exact Sciences were worth $1,546,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Perigon Wealth Management LLC boosted its position in Exact Sciences by 3.2% during the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after purchasing an additional 264 shares in the last quarter. Sanctuary Advisors LLC boosted its holdings in Exact Sciences by 2.0% in the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock worth $763,000 after acquiring an additional 269 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in Exact Sciences by 2.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock worth $812,000 after acquiring an additional 300 shares in the last quarter. CIBC Asset Management Inc boosted its holdings in Exact Sciences by 6.1% in the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after acquiring an additional 371 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in Exact Sciences by 3.5% in the third quarter. Intech Investment Management LLC now owns 11,986 shares of the medical research company’s stock worth $816,000 after acquiring an additional 402 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Bank of America lowered their price target on Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Royal Bank of Canada assumed coverage on Exact Sciences in a report on Thursday, March 13th. They issued a “sector perform” rating and a $52.00 price target for the company. Barclays lowered their price target on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Finally, BTIG Research lifted their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $70.83.

Exact Sciences Stock Up 3.0 %

Shares of EXAS stock opened at $45.62 on Friday. The stock has a 50 day moving average of $50.55 and a 200 day moving average of $58.28. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The stock has a market cap of $8.47 billion, a P/E ratio of -8.19 and a beta of 1.25. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. As a group, sell-side analysts expect that Exact Sciences Co. will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.